HomepageGNLX • NASDAQ
add
Genelux Corp
Vorige slotkoers
$ 2,69
Dag-range
$ 2,58 - $ 2,74
Jaar-range
$ 1,99 - $ 8,54
Beurswaarde
121,17 mln. USD
Gem. volume
196,11K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 8,19 mln. | 18,05% |
Netto inkomsten | -7,95 mln. | -22,93% |
Netto winstmarge | — | — |
Winst per aandeel | -0,21 | -10,53% |
EBITDA | -8,13 mln. | -18,11% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 20,92 mln. | -38,59% |
Totale activa | 24,99 mln. | -37,95% |
Totale passiva | 6,40 mln. | -10,91% |
Totaal aandelenvermogen | 18,59 mln. | — |
Uitstaande aandelen | 37,62 mln. | — |
Koers-boekwaardeverhouding | 5,49 | — |
Rendement op activa | -71,58% | — |
Rendement op kapitaal | -89,42% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -7,95 mln. | -22,93% |
Operationele kasstroom | -6,58 mln. | -14,39% |
Kasstroom uit beleggingen | 4,72 mln. | 18,26% |
Kasstroom uit financiering | 0,00 | — |
Nettomutatie in liquide middelen | -1,85 mln. | -5,58% |
Vrije kasstroom | -4,10 mln. | -27,13% |
Over
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Opgericht
2001
Hoofdvestiging
Website
Werknemers
24
